Investegate |Cardiol Therapeutics Announcements | Cardiol Therapeutics: Original-Research: Cardiol Therapeutics (von GBC AG):
Analyst: Julien Desrosiers; Felix Haugg The Company announced topline results from its Phase I Single and Multiple Ascending Dose Clinical Trial of CardiolRx(TM). CardiolRx is a pharmaceutically produced oral cannabidiol formulation being developed for the treatment of acute and chronic inflammation associated with heart disease. These results positively support Cardiol Therapeutics' proposed treatment dosage for their upcoming CardiolRx Phase II and Phase II/III trials. David Elsley, President and CEO of Cardiol Therapeutics, stated: 'Cardiol is initiating a Phase II/III clinical trial in th...
Source: investegate.co.uk